For research use only. Not for human or veterinary consumption. Not FDA-approved for the diagnosis, treatment, cure, or prevention of any disease.
Overview
GHK-Cu (glycyl-L-histidyl-L-lysine copper(II) complex) is a naturally occurring tripeptide-copper complex identified in human plasma, saliva, and urine. First isolated by Pickart in 1973, GHK binds copper(II) ions with high affinity and has been the subject of extensive preclinical research examining its role in cellular signaling, gene expression regulation, tissue remodeling, and antioxidant response pathways.
In its synthetic research form, GHK-Cu is supplied as a lyophilized powder for use in in vitro and in vivo experimental models. It is not approved by the FDA for any therapeutic application. GHK-Cu is currently the fastest-growing peptide in search interest, with year-over-year growth exceeding 1,000% as of 2026, reflecting expanding preclinical research interest in neuroprotective, wound healing, and epigenetic modulation models.
Molecular Properties
| Property | Value |
|---|---|
| Full Name | Glycyl-L-histidyl-L-lysine copper(II) complex |
| Abbreviation | GHK-Cu |
| Molecular Formula | C₁₄H₂₃CuN₆O₄ |
| Molecular Weight | 403.90 g/mol (copper complex) |
| CAS Number | 89030-95-5 |
| Amino Acid Sequence | Gly-His-Lys |
| Physical Form | Lyophilized blue-tinged powder |
| Storage | −20°C, desiccated, protected from light |
| Solubility | Aqueous (sterile water or PBS) |
Biochemical Mechanism
GHK-Cu functions as a copper-binding tripeptide with pleiotropic effects on cellular signaling cascades. Its biological activity in research models is attributed to several primary mechanisms.
Copper Ion Delivery
GHK binds Cu²⁺ with a stability constant of approximately 10¹⁷ M⁻¹ — substantially higher than that of albumin — and has been proposed to function as a physiological copper-transport molecule. Copper is an essential cofactor for multiple metalloenzymes including lysyl oxidase (critical for collagen cross-linking), superoxide dismutase, and cytochrome c oxidase.
TGF-β1 Modulation
Preclinical research has documented GHK-Cu’s modulatory effect on transforming growth factor beta-1 (TGF-β1) signaling. Studies in wound healing models have associated this interaction with alterations in fibroblast proliferation and collagen synthesis parameters, with concentration-dependent effects observed in cell culture systems.
Gene Expression Effects
Pickart et al. (2012) conducted gene expression profiling studies documenting GHK-Cu’s broad effects on human gene expression. Using Broad Institute Connectivity Map (CMAP) data, the authors identified associations between GHK-Cu and genes involved in ubiquitin-proteasome pathway regulation, DNA repair mechanisms, and anti-inflammatory signaling networks.
Angiogenic Pathway Involvement
In vitro investigations have examined GHK-Cu’s interaction with vascular endothelial growth factor (VEGF) pathways in endothelial cell culture systems. Studies in Matrigel plug assays in rodent models have documented effects on vascular network formation parameters.
Preclinical Research Applications
Wound Healing and Dermal Models
The most extensively published body of GHK-Cu research involves wound healing and skin biology models. Skin contraction assays, collagen gel contraction studies, and in vivo excisional wound models in rodents have constituted the primary experimental systems. The compound has been investigated in the context of collagenase activity, keratinocyte migration, and dermal extracellular matrix remodeling.
Neuroprotection Models
Recent preclinical literature has expanded the GHK-Cu research context into neuroscience. Huang et al. (2015) examined GHK-Cu in Alzheimer’s disease-relevant cell models, documenting effects on amyloid beta aggregation parameters and oxidative stress markers. Subsequent studies have examined the compound in models of traumatic brain injury and neuroinflammation.
Antioxidant and Anti-inflammatory Systems
GHK-Cu has been investigated in cell culture systems examining reactive oxygen species (ROS) management, with particular attention to superoxide dismutase (SOD) and catalase activity in treated versus control conditions.
Epigenetic Research
The compound’s interaction with SIRT1 and HDAC pathways has been examined in epigenetic contexts, with gene expression studies suggesting broad regulatory scope across multiple cellular processes.
Regulatory Status (US)
GHK-Cu occupies a favorable regulatory position relative to other research peptides. As a tripeptide with a long history of published preclinical literature and cosmetic research applications, it is not listed in the FDA Category 2 compounding prohibition list and is widely available as a research compound under RUO framework. GHK-Cu topical formulations have regulatory precedent in cosmetic applications, separate from RUO research vials.
Peptrio’s GHK-Cu Product Line
Peptrio offers GHK-Cu in two research formats. The GHK-Cu 50mg injectable-grade lyophilized powder is verified to ≥99% purity by HPLC, with identity confirmed by LC-MS, and ships with a batch-specific CoA from an ISO/IEC 17025 accredited laboratory for use in in vitro and in vivo research. The GHK-Cu Topical Cream (50mg) is suspended in a topical vehicle for dermal research model applications only, and is not intended for systemic or human therapeutic use.
Analytical Verification Standards
Research-grade GHK-Cu procurement should meet the following minimum criteria. Purity ≥99% by HPLC: the copper complex is measurable by reverse-phase HPLC; the chromatogram should show the target peak with ≤1% aggregate impurity area. LC-MS Identity Confirmation: for GHK-Cu, the expected mass corresponds to the copper complex (403.90 g/mol) or the free peptide GHK (340.38 g/mol) depending on the form supplied. Batch-Specific CoA: lot-specific documentation is required for experimental reproducibility and audit trail integrity. ISO/IEC 17025 Accredited Testing: third-party laboratory accreditation verifies the competence of the analytical methodology applied.
Frequently Asked Questions
What is GHK-Cu used for in research?
GHK-Cu is investigated in preclinical research models examining wound biology, collagen remodeling, neuroprotection, angiogenesis, and gene expression regulation. All applications are in vitro or in vivo experimental models only; GHK-Cu is not approved for any human therapeutic use.
What is the difference between GHK and GHK-Cu?
GHK refers to the free tripeptide (glycyl-L-histidyl-L-lysine), while GHK-Cu is the copper(II) complex. Most preclinical research has been conducted on the copper-bound form, as copper coordination is believed to be integral to its biological activity in cell-based assay systems.
Why is GHK-Cu growing so rapidly in research interest?
The expansion of GHK-Cu research interest reflects growing investigation in neuroprotective models, expansion of longevity and epigenetics research programs, and crossover from cosmetic formulation research into RUO experimental science.
Is GHK-Cu subject to FDA compounding restrictions?
As of March 2026, GHK-Cu is not on the FDA’s Category 2 prohibited substances list for compounding. However, all Peptrio GHK-Cu products are sold exclusively as Research Use Only compounds and are not represented as compounding ingredients.
Disclaimer: GHK-Cu is available from Peptrio for research use only. Not for human or veterinary consumption. Not FDA-approved for any medical application. All research use must be conducted by qualified research professionals in appropriate laboratory settings.
Selected PubMed References:
Pickart L, Margolina A. Int J Mol Sci. 2018;19(7):1987. PMID: 29987209
Pickart L, et al. Biomed Res Int. 2015;2015:648108. PMID: 26236731
Pickart L. J Biomater Sci Polym Ed. 2008;19(8):969-88. PMID: 18644225
Huang PJ, et al. Neurotoxicology. 2015;47:37-44.